Pentraxin-3 Attenuates Renal Damage in Diabetic Nephropathy by Promoting M2 Macrophage Differentiation

详细信息    查看全文

• 作者：Huaibin Sun ; Jun Tian ; Wanhua Xian ; Tingting Xie ; Xiangdong Yang
• 关键词：pentraxin ; 3 ; M2 macrophage ; diabetic nephropathy
• 刊名：Inflammation
• 出版年：2015
• 出版时间：October 2015
• 年：2015
• 卷：38
• 期：5
• 页码：1739-1747
• 全文大小：1,593 KB
• 参考文献：1.Dronavalli, S., I. Duka, and G.L. Bakris. 2008. The pathogenesis of diabetic nephropathy. Nature Clinical Practice Endocrinology & Metabolism 4: 444-52.CrossRef
  2.Alvarez, M.L., and J.K. Distefano. 2013. The role of non-coding RNAs in diabetic nephropathy: potential applications as biomarkers for disease development and progression. Diabetes Research and Clinical Practice 99: 1-1.CrossRef PubMed
  3.Sun, Y.M., Y. Su, J. Li, and L.F. Wang. 2013. Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy. Biochemical and Biophysical Research Communications 433: 359-61.CrossRef PubMed
  4.Bozza, S., F. Bistoni, R. Gaziano, L. Pitzurra, T. Zelante, P. Bonifazi, et al. 2006. Pentraxin 3 protects from MCMV infection and reactivation through TLR sensing pathways leading to IRF3 activation. Blood 108: 3387-396.CrossRef PubMed
  5.Garlanda, C., B. Bottazzi, A. Bastone, and A. Mantovani. 2005. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annual Review of Immunology 23: 337-66.CrossRef PubMed
  6.Cieslik, P., and A. Hrycek. 2012. Long pentraxin 3 (PTX3) in the light of its structure, mechanism of action and clinical implications. Autoimmunity 45: 119-28.CrossRef PubMed
  7.Yamasaki, K., M. Kurimura, T. Kasai, M. Sagara, T. Kodama, and K. Inoue. 2009. Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations. Clinical Chemistry and Laboratory Medicine 47: 471-77.CrossRef PubMed
  8.Dubin, R., Y. Li, J.H. Ix, M.G. Shlipak, M. Whooley, and C.A. Peralta. 2012. Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study. American Heart Journal 163: 274-79.PubMed Central CrossRef PubMed
  9.Tong, M., J.J. Carrero, A.R. Qureshi, B. Anderstam, O. Heimburger, P. Barany, et al. 2007. Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clinical Journal of the American Society of Nephrology 2: 889-97.CrossRef PubMed
  10.Suliman, M.E., M.I. Yilmaz, J.J. Carrero, A.R. Qureshi, M. Saglam, O.M. Ipcioglu, et al. 2008. Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. Clinical Journal of the American Society of Nephrology 3: 976-85.PubMed Central CrossRef PubMed
  11.Meuwese, C.L., J.J. Carrero, and P. Stenvinkel. 2011. Recent insights in inflammation-associated wasting in patients with chronic kidney disease. Contributions to Nephrology 171: 120-26.CrossRef PubMed
  12.Daigo, K., M. Nakakido, R. Ohashi, R. Fukuda, K. Matsubara, T. Minami, et al. 2014. Protective effect of the long pentraxin PTX3 against histone-mediated endothelial cell cytotoxicity in sepsis. Science Signaling 7: a88.CrossRef
  13.Miyamoto, T., Q.A. Rashid, O. Heimburger, P. Barany, K. Carrero, B. Sjoberg, et al. 2011. Inverse relationship between the inflammatory marker pentraxin-3, fat body mass, and abdominal obesity in end-stage renal disease. Clinical Journal of the American Society of Nephrology 6: 2785-791.PubMed Central CrossRef PubMed
  14.Osorio-Conles, O., M. Guitart, M.R. Chacon, E. Maymo-Masip, J.M. Moreno-Navarrete, M. Montori-Grau, et al. 2011. Plasma PTX3 protein levels inversely correlate with insulin secretion and obesity, whereas visceral adipose tissue PTX3 gene expression is increased in obesity. American Journal of Physiology Endocrinology and Metabolism 301: E1254–E1261.CrossRef PubMed
  15.Abu, S.N., A. Witasp, M.W. Wan, B. Anderstam, K. Brismar, P. Stenvinkel, et al. 2013. Evaluation of the association of plasma pentraxin 3 levels with type 2 diabetes and diabetic nephropathy in a Malay population. Journal of Diabetes Research 2013: 298019.
  16.Pichaiwong, W., K.L. Hudkins, T. Wietecha, T.Q. Nguyen, C. Tachaudomdach, W. Li, et al. 2013. Reversibility of structural and functional damage in a model of advanced diabetic nephropathy. Journal of the American Society of Nephrology 24: 1088-102.PubMed Central CrossRef PubMed
  17.Yuen, D.A., B.E. Stead, Y. Zhang, K.E. White, M.G. Kabir, K. Thai, et al. 2012. eNOS deficiency predisposes podocytes to injury in diabetes. Journal of the American Society of Nephrology 23: 1810-823.PubMed Central CrossRef PubMed
  18.Inoki, K., H. Mori, J. Wang, T. Suzuki, S. Hong, S. Yoshida, et al. 2011. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. The Journal of Clinical Investigation 121: 2181-196.PubMed Central CrossRef PubMed
  19.George, B., R. Verma, A.A. Soofi, P. Garg, J. Zhang, T.J. Park, et al. 2012. Crk1/2-dependent signaling is necessary for podocyte foot process spreading in mouse models of glomerular disease. The Journal of Clinical Investigation 122: 674-92.PubMed Central Cr
• 作者单位：Huaibin Sun (1)
  Jun Tian (1)
  Wanhua Xian (1)
  Tingting Xie (2)
  Xiangdong Yang (2)
  
  1. Department of Hemodialysis, Qilu Hospital, Shandong University, Jinan, China
  2. Department of Nephrology, Qilu Hospital, Shandong University, 107 Wenhuaxi Road, Jinan, Shandong, 250012, China
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Rheumatology
  Internal Medicine
  Pharmacology and Toxicology
  Pathology
  
• 出版者：Springer Netherlands
• ISSN：1573-2576

文摘

As one of the most important long-term complications of diabetes, diabetic nephropathy (DN) is the major cause of end-stage renal disease and high mortality in diabetic patients. The long pentraxin 3 (Ptx3) is a member of a superfamily of conserved proteins characterized by a cyclic multimeric structure and a conserved C-terminal domain. Several clinical investigations have demonstrated that elevated plasma Ptx3 levels are associated with cardiovascular and chronic kidney diseases (CKD). However, the therapeutic effect of Ptx3 on DN has never been investigated. In our current study, we showed a crucial role for Ptx3 in attenuating renal damage in DN. In our mouse hyperglycemia-induced nephropathy model, Ptx3 treatment showed significantly increased expression of nephrin, acetylated nephrin, and Wilm’s tumor-1 protein (WT-1) when compared with control. The number of CD4+ T cells, CD8+ T cells, Ly6G+ neutrophils, and CD11b+ macrophages were all significantly lower in the Ptx3-treated group than that in the control group in DN. The IL-4 and IL-13 levels in the Ptx3-treated group were markedly higher than that in the control group in DN. Correspondingly, the Ptx3-treated group showed increased numbers of Arg1- or CD206-expressing macrophages compared with the control group. Furthermore, inhibition of Ptx3-treated macrophages abrogated the alleviated renal damage induced by Ptx3 treatment. In conclusion, Ptx3 attenuates renal damage in DN by promoting M2 macrophage differentiation. KEY WORDS pentraxin-3 M2 macrophage diabetic nephropathy